Evolus to Participate in The Jefferies Global Healthcare Conference
Evolus, Inc. announced its management team will participate in a fireside chat and investor meetings at the Jefferies Global Healthcare Conference in New York City. The fireside chat is scheduled for June 4, 2026, at 12:50 PM ET and will be accessible via webcast on the Evolus Investor Relations page. Evolus is a performance beauty company focused on aesthetic injectables with products like Jeuveau® and Evolysse™.
Evolus to Participate in The Jefferies Global Healthcare Conference
Evolus, Inc. (NASDAQ: EOLS) announced that its management team will participate in a fireside chat and investor meetings at the upcoming Jefferies Global Healthcare Conference in New York City on June 4th, 2026. The company, a performance beauty leader, will have its fireside chat accessible via webcast on its investor relations page, with a replay available for 90 days. Evolus aims to redefine the aesthetic injectable market with products like Jeuveau® and Evolysse™.
Earnings call transcript: Evolus Inc Q1 2026 misses EPS forecast, stock rises
Evolus Inc. reported a Q1 2026 EPS miss at -$0.16 against a -$0.11 forecast, but revenue slightly exceeded expectations at $73.1 million. Despite the EPS shortfall, the company's stock experienced a significant 19.51% increase in after-hours trading, driven by strong revenue growth and positive Adjusted EBITDA. Evolus reiterated its full-year 2026 guidance, expecting continued double-digit revenue growth and Adjusted EBITDA profitability, with upcoming product launches like Estyme in Europe and anticipated FDA approval for Sculpt.
Evolus To Roll Out Estyme Injectable Hyaluronic Acid Fillers in Europe
Evolus, Inc. announced the official launch of its Estyme injectable hyaluronic acid (HA) gel collection in Europe on May 16, 2026. The collection includes four HA gels, with Estyme Smooth and Estyme Form already marketed in the U.S. as Evolysse, and the debut of Estyme Lips and Estyme Sculpt for Europe. This launch follows CE Mark certification and positions Evolus as a multi-product aesthetics company, particularly with the potential leader Estyme Sculpt for mid-face volumizing.
Evolus (EOLS) to Launch Estyme Injectable Collection in Europe
Evolus Inc. (EOLS) announced the upcoming launch of its Estyme line of injectable hyaluronic acid gels in Europe on May 16th, marking its entry into the global dermal filler market. While this expansion presents a significant growth opportunity for Evolus, the company also exhibits notable financial weaknesses and a trend of insider selling, urging caution for potential investors. Evolus has a GF Score™ of 62/100, indicating moderate overall performance, but shows strong growth potential alongside poor financial strength and profitability ratings.
Evolus Announces Commercial Launch Of Estyme® Injectable Hyaluronic Acid Gels In Europe
Evolus Inc. (EOLS) announced the commercial launch of its Estyme® injectable hyaluronic acid gels in Europe. This marks a significant expansion for the company into the European aesthetics market. The product is designed to offer a new option for patients seeking hyaluronic acid-based aesthetic treatments.
Evolus May 2026 slides: HA innovation, Jeuveau data support dual strategy
Evolus Inc. presented comprehensive clinical data for its Evolysse hyaluronic acid filler line, featuring its proprietary Cold-X™ Technology, and its Jeuveau neuromodulator. The company highlighted strong efficacy and safety profiles for both product lines in various aesthetic indications, including statistical superiority for Evolysse Form against a comparator. Evolus also discussed an extra-strength Jeuveau formulation and outlined its commercial roadmap for upcoming product launches, reinforcing its dual-product strategy and positive market outlook.
Earnings call transcript: Evolus Inc Q1 2026 misses EPS forecast, stock rises
Evolus Inc. (NASDAQ:EOLS) reported its Q1 2026 earnings, missing EPS forecasts but exceeding revenue expectations with $73.1 million. The stock surged 19.51% in after-hours trading, driven by a 7% year-over-year revenue increase and a second consecutive quarter of positive Adjusted EBITDA, despite an EPS of -$0.16 against a -$0.11 forecast. The company reiterated its full-year 2026 guidance for revenue and profitability, expressing confidence in its strategic priorities and market recovery for aesthetic products.
Evolus Faces Heightened Operational Risk from Overseas Manufacturing and Disaster Recovery Gaps
Evolus, Inc. (EOLS) is exposed to significant operational risks due to its reliance on overseas third-party manufacturers, which could lead to supply disruptions, affect clinical development, and harm the company financially and reputationally. The company also faces potential issues from inadequate disaster recovery and business continuity plans, which could result in substantial costs and prolonged downtime. Analysts currently project a 127.63% upside potential for EOLS stock, with an average price target of $14.50.
Evolus, Inc. (NASDAQ:EOLS) Q1 2026 Earnings Call Transcript
Evolus, Inc. reported strong Q1 2026 results, exceeding earnings expectations and achieving positive adjusted EBITDA for the second consecutive quarter. The company maintained Jeuveau's U.S. market share at 14% and delivered share gains with Evolisse, emphasizing its differentiated commercial model and leveraging AI for efficiency. Evolus reiterated its full-year 2026 outlook, projecting double-digit revenue growth and full-year adjusted EBITDA profitability, while also planning for the international launch of Esteem and FDA approval for Sculp.
Evolus Posts Mixed Q1 Results
Evolus Inc. reported mixed first-quarter results, exceeding revenue expectations with a 7% increase to $73.1 million, but also posting a wider net loss of 16 cents compared to an anticipated 11-cent loss. The aesthetics company, known for its product Jeuveau, reaffirmed its full-year revenue guidance of $327 million to $337 million, representing 10% to 13% growth. Following the announcement, Evolus shares saw a slight rise in after-hours trading.
Evolus, Inc. 1Q 2026: Revenue $73.14M, EPS ($0.16) — 10-Q Summary
Evolus, Inc. reported its first-quarter 2026 results, showing a 6.7% year-over-year revenue increase to $73.14M and a reduction in net loss to ($10.67M). Diluted loss per share improved to ($0.16) compared to ($0.3) in the prior year. This growth was attributed to the Evolysse® launch and the international expansion of Jeuveau® in various markets.
Evolus Inc. (EOLS) stock falls on Q1 2026 Earnings
Evolus Inc. (EOLS) reported Q1 2026 revenue of $73.1 million, below analyst estimates, leading to a stock decline. The company experienced a decrease in net income, diluted EPS, and cash from operating activities year-over-year. Insider selling and significant hedge fund activity, including both reductions and additions to positions, were also noted.
Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook
Evolus, Inc. reported its first-quarter 2026 financial results, achieving its second consecutive quarter of positive Adjusted EBITDA with $0.6 million and global net revenue of $73.1 million, a 7% increase year-over-year. The company reaffirmed its full-year 2026 net revenue guidance of $327 million to $337 million and anticipates achieving a low- to mid-single-digit Adjusted EBITDA margin in 2026. This performance was driven by strong demand for Jeuveau® and growing momentum for Evolysse®, along with an expanding loyalty program and strategic international launches.
Evolus (NASDAQ: EOLS) Q1 2026 earnings, guidance and growth outlook
Evolus (NASDAQ: EOLS) reported Q1 2026 net revenue of $73.1 million, a 7% increase year-over-year, and achieved positive Adjusted EBITDA of $0.6 million for the second consecutive quarter. The company reaffirmed its full-year 2026 net revenue guidance of $327–$337 million and a low- to mid-single digit Adjusted EBITDA margin, while also setting a long-term target of $450–$500 million in revenue and 13–15% Adjusted EBITDA margins by 2028. Evolus noted potential impacts from a proposed 15% U.S. tariff on patented pharmaceuticals from South Korea but expressed confidence in mitigating near- to medium-term effects.
Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook
Evolus, Inc. reported its first-quarter 2026 financial results, highlighting a second consecutive quarter of positive Adjusted EBITDA, reaching $0.6 million. The company reaffirmed its full-year 2026 net revenue guidance of $327 million to $337 million and non-GAAP operating expenses of $210 million to $216 million, expecting to achieve a low- to mid-single-digit Adjusted EBITDA margin. These results reflect continued business strength, structural improvements, and growing customer engagement with its Jeuveau® and Evolysse® products, alongside strategic portfolio expansion.
Evolus Q1 2026 earnings preview
This article provides a preview of Evolus's Q1 2026 earnings. As a medical aesthetics company, its performance is often watched for insights into the growth of the cosmetic treatment market. Investors will be keen to see if the company's financial results meet expectations.
Evolus Inc expected to post a loss of 13 cents a share - Earnings Preview
Evolus Inc (EOLS) is projected to report a loss of 13 cents per share, according to a recent earnings preview. This forecast comes from Refinitiv. The article provides a brief update on the company's expected financial performance.
[ARS] Evolus, Inc. SEC Filing
This article announces an ARS SEC filing by Evolus, Inc. (EOLS) with a neutral sentiment and low impact. The filing was accepted on April 29, 2026, and is available as a PDF document. The article also provides a brief overview of Evolus, including its market cap ranking and recent news and SEC filings.
Evolus Deadline Alert
Faruqi & Faruqi, LLP is investigating potential claims against Evolus, Inc. (NASDAQ: EOLS) and reminds investors of the December 15, 2020 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Evolus misappropriated trade secrets regarding its botulinum toxin product, Jeuveau™, leading to a significant drop in stock price after a U.S. International Trade Commission ruling. Investors who suffered losses exceeding $100,000 between February 1, 2019, and July 6, 2020, are encouraged to contact the firm.
Evolus, Inc. (NASDAQ:EOLS) Given Consensus Rating of "Moderate Buy" by Analysts
Evolus, Inc. (NASDAQ:EOLS) has received a consensus "Moderate Buy" rating from six brokerages, with an average 12-month target price of $16.00. The company recently reported Q4 earnings where revenue exceeded expectations at $90.3 million, though EPS was $0.00 against an anticipated $0.09. Insiders have sold a total of 163,504 shares worth $797,184 in the past 90 days, yet institutional investors hold a significant 90.69% of the stock.
Evolus (NasdaqGM:EOLS) Stock Forecast & Analyst Predictions
Evolus (NasdaqGM:EOLS) is forecast to significantly grow earnings and revenue over the next few years, with EPS expected to increase by 64.9% per annum. Despite this positive outlook, analysts have recently lowered their price targets on Evolus due to adjusted assumptions regarding long-term revenue growth and more conservative guidance for 2025 and 2026. The company is expected to become profitable within the next three years, outpacing the savings rate and the broader market growth.
Short Interest in Evolus, Inc. (NASDAQ:EOLS) Drops By 14.4%
Evolus, Inc. (NASDAQ:EOLS) experienced a 14.4% decrease in short interest in March, totaling 6,517,006 shares by March 31st, which represents 10.6% of its stock and a 6.6-day short-interest ratio. Insider sales also occurred, with David Moatazedi selling 116,720 shares and Rui Avelar selling 29,996 shares, reducing their ownership. Despite institutional ownership being high at 90.69% and a "Moderate Buy" consensus from analysts with a $16 price target, the stock is trading near $4.69 following a recent EPS miss.
Evolus, Inc. (NASDAQ:EOLS) Q4 2025 earnings call transcript
This entry indicates the availability of the Q4 2025 earnings call transcript for Evolus, Inc. (NASDAQ:EOLS). This crucial document provides a detailed overview of the company's financial performance and strategic outlook discussed during the call. Investors and analysts can use this resource to gain insights into the company's recent results and future plans.
Evolus (LTS:0K16) PB Ratio : (As of Apr. 10, 2026)
This article from GuruFocus examines Evolus (LTS:0K16) Price-to-Book (PB) Ratio as of April 11, 2026. It elaborates on the calculation of the PB Ratio, provides historical data and industry comparisons, and notes that Evolus' stock appears to be undervalued according to GuruFocus' GF Value™. The company's business description highlights its focus on aesthetic medicine with its flagship product, Jeuveau.
Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference
Evolus, Inc. announced that its management team will participate in a fireside chat and investor meetings at the Needham 25th Annual Virtual Healthcare Conference on Tuesday, April 14, 2026, at 3:45 PM ET. The fireside chat will be accessible via their Investor Relations page, with a replay available for 90 days. Evolus is a performance beauty company focused on aesthetic injectables like Jeuveau and Evolysse.
Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference
Evolus, Inc. announced its management team will participate in a fireside chat and investor meetings at the Needham 25th Annual Virtual Healthcare Conference on April 14, 2026, at 3:45 PM ET. The performance beauty company focuses on building an aesthetic portfolio of consumer brands and redefining the aesthetic injectable market. A webcast of the fireside chat will be available on the Investor Relations page of the Evolus website.
Evolus, Inc. (NASDAQ:EOLS) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Evolus, Inc. (NASDAQ:EOLS) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $16.00. Despite this, insiders have recently sold a significant number of shares, and the company's stock is trading near its 1-year low after missing quarterly EPS estimates. Institutional investors, however, have shown mixed activity, with some increasing and some decreasing their stakes.
Vanguard disaggregates holdings for Evolus (NASDAQ: EOLS) after internal realignment
The Vanguard Group has filed an amended Schedule 13G for Evolus (EOLS), reporting 0% beneficial ownership of the common stock. This change is due to an internal realignment within Vanguard, leading to disaggregated reporting by its subsidiaries in accordance with SEC Release No. 34-39538, effective January 12, 2026. The filing explicitly states that this is a procedural change in reporting structure and does not indicate a sale of shares by Vanguard.
Avelar Rui sells Evolus (EOLS) shares worth $14815
Rui Avelar, an officer at Evolus, Inc. (NASDAQ:EOLS), sold 3,119 shares of common stock worth $14,815 on March 20, 2026, at a weighted average price of $4.75. This transaction was part of a Rule 10b5-1 trading plan to cover tax withholding obligations related to restricted stock unit awards. The sale occurred while the stock is trading near its 52-week low, and comes amidst recent news of Evolus missing Q4 2025 revenue expectations and a board reclassification.
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. (NASDAQ: EOLS) granted 85,516 restricted stock units (RSUs) and 8,635 stock options to 10 newly hired non-executive employees in March 2026. These inducement awards were approved by the compensation committee under the company's 2023 Inducement Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4). The awards vest 25% annually and are subject to continuous employment.
Evolus (NASDAQ: EOLS) insider sells 13,669 shares to cover taxes
Evolus (NASDAQ: EOLS) director and officer David Moatazedi sold 13,669 shares of common stock at a weighted average price of $4.7501 per share under a Rule 10b5-1 trading plan. This sale was conducted to cover tax withholding obligations associated with restricted stock unit awards. Following the transaction, Moatazedi retains a direct holding of 604,700 Evolus shares, indicating a tax-driven adjustment rather than a change in his equity position.
Avelar Rui sells Evolus (EOLS) shares worth $14815
Rui Avelar, an officer at Evolus, Inc. (NASDAQ:EOLS), sold 3,119 shares of common stock for $14,815 to cover tax withholding obligations. This transaction occurred as the stock trades near its 52-week low. The company recently reported a slight miss in Q4 2025 revenue expectations and a change in its board of directors.
Evolus CEO Moatazedi sells $64929 in shares
Evolus, Inc. CEO David Moatazedi sold 13,669 shares of common stock for approximately $64,929 on March 20, 2026, to cover tax withholding obligations. The company's stock has declined 30% year-to-date and is trading near its 52-week low. Despite the stock performance, two analysts have recently revised earnings upward, though the company missed fourth-quarter 2025 revenue expectations.
Evolus (EOLS) officer tax-driven sale of 3,119 shares under 10b5-1 plan
Evolus, Inc. officer Rui Avelar sold 3,119 shares of common stock at a weighted average price of $4.75 per share. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan to cover tax withholding obligations from restricted stock unit settlements. Following the transaction, Avelar directly holds 427,423 Evolus shares, indicating it was a small, tax-related sale.
Avelar Rui, chief medical officer at Evolus, sells $146k in EOLS stock
Avelar Rui, Chief Medical Officer at Evolus, Inc. (NASDAQ:EOLS), sold nearly $146,629 worth of company stock after the vesting of restricted stock units. Following the transaction, Rui directly holds 430,542 shares of Evolus. This sale occurred shortly after Evolus reported a slight miss on Q4 2025 revenue expectations and announced changes to its board of directors.
David Moatazedi Sells 116,720 Shares of Evolus (NASDAQ:EOLS) Stock
David Moatazedi, an insider at Evolus (NASDAQ:EOLS), sold 116,720 shares of the company's stock on March 17th for a total of $570,760.80, reducing his ownership by 15.88%. This sale comes as the stock trades near its 50-day moving average, and after the company reported an EPS miss for the quarter. Despite the insider sale and EPS miss, analysts maintain a "Moderate Buy" consensus rating with an average price target of $16.00.
Insider Selling: Evolus (NASDAQ:EOLS) Insider Sells 29,996 Shares of Stock
Evolus (NASDAQ:EOLS) insider Rui Avelar sold 29,996 shares of the company's stock for approximately $146,680.44 on March 17th, reducing his stake by 6.51%. The sale followed the company reporting $0.00 EPS, missing estimates, and shares have since traded down. Analysts have a "Moderate Buy" consensus rating with an average price target of $16.00, despite mixed views.
Avelar Rui, chief medical officer at Evolus, sells $146k in EOLS stock
Avelar Rui, Chief Medical Officer at Evolus, Inc. (NASDAQ:EOLS), sold nearly $147,000 worth of company stock to cover tax withholding obligations following the vesting of performance restricted stock units. Despite this sale, Avelar Rui still directly owns over 430,000 shares. The company recently reported a slight miss on Q4 2025 revenue expectations and made changes to its board of directors to maintain governance balance.
[Form 4] Evolus, Inc. Insider Trading Activity
Evolus, Inc. director and officer David Moatazedi reported insider trading activity, including the vesting of 67,489 performance restricted stock units and the subsequent sale of 116,720 shares of common stock. These sales, executed under a Rule 10b5-1 trading plan, were primarily to cover tax withholding obligations related to the equity awards. Following these transactions, Moatazedi's direct holdings in Evolus common stock stand at 618,369 shares.
Evolus CEO Moatazedi sells $570k in shares
Evolus CEO David Moatazedi sold 116,720 shares of company stock worth approximately $570,562 on March 17, 2026, primarily to cover tax obligations related to vesting stock units. This transaction occurred under a pre-arranged trading plan, and despite the sale, Moatazedi maintains a direct ownership of over 618,000 shares. The company's shares are currently trading near a 52-week low, and recent earnings reports indicate a slight revenue miss, though some analysts have revised earnings estimates upward.
Evolus (EOLS) executive sells 29,996 shares after PSU vesting
Evolus executive Rui Avelar sold 29,996 shares of common stock at a weighted average price of $4.8883 per share to cover tax obligations following the vesting of performance restricted stock units (PSUs). On March 16, 2026, 8,804 PSUs vested, with an additional 8,802 PSUs scheduled to vest in February 2027. After these transactions, Avelar directly holds 430,542 shares of Evolus common stock.
(EOLS) as a Liquidity Pulse for Institutional Tactics
Evolus Inc. (NASDAQ: EOLS) is highlighted with a near-term weak sentiment, a mid-channel oscillation pattern, and an exceptional risk-reward setup targeting a 24.2% gain. The article provides three institutional trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss zones. It also includes a multi-timeframe signal analysis, showing varying signal strengths and support/resistance levels for different time horizons.
Evolus, Inc. Files Form 8-K Announcing Executive Changes and Company Information (March 13, 2026)
Evolus, Inc. filed a Form 8-K to announce executive changes reclassifying an existing director, Mr. Malik, to Class II to rebalance the board structure after a resignation. The board remains at six directors, evenly distributed among three classes, with no new compensation or related-party transactions for Mr. Malik. This administrative update ensures proper corporate governance without impacting company leadership or shareholder compensation.
Evolus (EOLS) reclassifies chairman Vikram Malik to restore board balance
Evolus, Inc. announced the reclassification of its Chairman, Vikram Malik, from Class III to Class II director to restore balance to its classified board. This technical change was necessitated by the departure of a former director, Simone Blank, and ensures an even distribution of two directors across each of the three board classes. Malik's continuous service on the board, his role as Chairman, and his existing equity awards remain unaffected by this reclassification.
Evolus reclassifies Vikram Malik to Class II director to balance board
Evolus, Inc. announced the reclassification of Vikram Malik from a Class III to a Class II director to rebalance its board after a previous departure. Mr. Malik will continue as Chairman and a member of the Compensation Committee, serving until the 2026 annual meeting. The company's board now consists of six directors, with two in each class, and InvestingPro analysis suggests the stock is currently undervalued.
Vikram Malik reclassified to Class II director at Evolus
Evolus has reclassified Vikram Malik from a Class III to a Class II director, effective March 13, 2026. This change aims to restore balance among director classes after a previous departure, with Malik retaining his roles as Chairman and Compensation Committee member. His service on the board remains continuous, and his existing equity awards will continue to vest as originally planned.
Evolus reclassifies Vikram Malik to Class II director to balance board
Evolus (NASDAQ:EOLS) has reclassified Vikram Malik from a Class III to a Class II director to balance its board structure following a previous departure. Malik will continue as Chairman of the Board and a member of the Compensation Committee, with his existing equity awards remaining unchanged. This move ensures the board maintains two directors in each of its three classes.
Evolus, Inc. (NASDAQ:EOLS) Q4 2025 earnings call transcript
This document is a transcript of the Q4 2025 earnings call for Evolus, Inc. (NASDAQ:EOLS). It contains details of the company's financial performance and discussions held during the call.
Evolus (NASDAQ: EOLS) outlines 2025 losses, Jeuveau and Evolysse growth plans
Evolus Inc. (NASDAQ: EOLS) reported a net loss of $51.6 million in 2025, bringing its accumulated deficit to $661.0 million, despite an 11.6% increase in net revenues to $297.2 million, driven by the launch of Evolysse in the US and growth in Jeuveau sales. The company's strategy focuses on the cash-pay medical aesthetics market with its neurotoxin Jeuveau and hyaluronic acid gels Evolysse, planning further product launches in Europe and regulatory approvals in the US. Evolus highlights ongoing reliance on manufacturing and licensing partners, competitive pressures, and dependence on consumer discretionary spending as key challenges.
